<DOC>
	<DOCNO>NCT00576654</DOCNO>
	<brief_summary>This phase I trial study side effect best dose veliparib give together irinotecan hydrochloride treat patient cancer spread part body remove surgery . Irinotecan hydrochloride kill cancer cell damage deoxyribonucleic acid ( DNA ) need cancer cell survival growth . Veliparib may block protein repair damage DNA may help irinotecan hydrochloride kill tumor cell . Giving irinotecan hydrochloride together veliparib may kill cancer cell .</brief_summary>
	<brief_title>Veliparib Irinotecan Hydrochloride Treating Patients With Cancer That Is Metastatic Can Be Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine optimal biologic dose ( OBD ) poly ( adenosine diphosphate [ ADP ] -ribose ) polymerase ( PARP ) inhibition use irinotecan ( irinotecan hydrochloride ) ( weekly intravenously 2 3 week ) , combination ABT-888 ( veliparib ) ( twice daily orally 2 3 week ) . ( ORIGINAL DOSE ESCALATION PORTION ) II . To determine recommended phase II dose ( RP2D ) irinotecan ( weekly intravenously 2 3 week ) , combination ABT-888 ( twice daily orally 2 3 week ) , determine evaluate feasibility , safety , dose limit toxicity maximally tolerate dose . ( ORIGINAL DOSE ESCALATION PORTION ) III . To determine safety profile irinotecan combination ABT-888 : incidence adverse event ( AEs ) clinically significant change laboratory test , electrocardiogram ( ECGs ) , vital sign . ( ORIGINAL DOSE ESCALATION PORTION ) IV . To determine safety profile irinotecan combination ABT-888 recommend phase II dose : incidence adverse event ( AEs ) clinically significant change laboratory test , ECGs , vital sign . ( ORIGINAL DOSE ESCALATION PORTION ) V. To determine recommended phase II dose ( RP2D ) drug irinotecan ( weekly intravenously 2 3 week ) , combination ABT-888 ( twice daily orally intermittent dose day 1 4 day 8 11 cycle ) , determine evaluate feasibility , safety , dose limit toxicity maximally tolerate dose ( MTD ) . ( DOSE ESCALATION FOR INTERMITTENT ABT-888 PORTION ) VI . To determine safety profile irinotecan combination ABT-888 : incidence adverse event ( AEs ) clinically significant change laboratory test , vital sign . ( DOSE ESCALATION FOR INTERMITTENT ABT-888 PORTION ) VII . To determine safety profile irinotecan combination ABT-888 recommend phase II dose : incidence adverse event ( AEs ) clinically significant change laboratory test , vital sign . ( DOSE ESCALATION FOR INTERMITTENT ABT-888 PORTION ) SECONDARY OBJECTIVES : I . To determine pharmacokinetic ( PK ) profile ABT-888 . II . To determine PK profile irinotecan ( CPT-11 ) single agent combination ABT-888 . III . To determine tumor response assess Response Evaluation Criteria Solid Tumors ( RECIST ) . IV . To determine tumor response assess Response Evaluation Criteria Solid Tumors ( RECIST ) . ( DOSE ESCALATION FOR INTERMITTENT ABT-888 PORTION ) V. To determine response rate ( RR ) patient . ( DOSE ESCALATION FOR INTERMITTENT ABT-888 PORTION ) TERTIARY OBJECTIVES : I. Pharmacodynamic ( PD ) biomarker response : PARP inhibition peripheral blood mononuclear cell ( PBMC ) measurement PAR level . ( ORIGINAL DOSE ESCALATION PORTION ) II . DNA damaging effect irinotecan combination irinotecan ABT-888 : level gamma H2A histone family , member X ( gamma-H2AX ) RAD51 recombinase ( Rad51 ) formation tumor tissue . ( ORIGINAL DOSE ESCALATION PORTION ) III . Relevance cytochrome P450 family 2 , subfamily C , polypeptide 9 ( CYP2C9 ) 2C19 polymorphism , uridine 5'-diphosphosphate ( UDP ) glucuronosyltransferase 1 family , polypeptide A1 ( UGT1A1 ) polymorphism , ATP-binding cassette , sub-family G ( WHITE ) , member 2 ( ABCG2 ) polymorphism pharmacokinetics irinotecan and/or ABT-888 . ( ORIGINAL DOSE ESCALATION PORTION ) IV . To explore whether positive gamma-H2AX response tumor tissue 4-6 hour ( hr ) reflect circulate tumor cell ( CTCs ) 8-24 hrs 4-6 hr , predict . ( EXPANSION PORTION ) V. To explore whether PARP inhibition increase gamma-H2AX response CTCs plasma drug 4-6 hr CPT-11 administration . ( EXPANSION PORTION ) VI . To explore whether PARP inhibition increase gamma-H2AX response tumor cell tissue drug level , indicate CTCs 8-24 hr CPT-11 . ( EXPANSION PORTION ) VII . To explore gamma-H2AX response peak CTCs occur , indicate response tumor . ( EXPANSION PORTION ) VIII . To explore whether tumor switch gamma-H2AX excision repair cross-complementation group 1 ( ERCC1 ) -mediated repair presence PARP inhibition , ( i.e. , repeat initial PBMC tumor finding ) . ( EXPANSION PORTION ) IX . To perform analysis CTCs day 15 help guide alteration ABT-888 drug administration schedule ( continuous administration ) . ( EXPANSION PORTION ) X . To sequence genome transcriptome normal tumor tissue study patient expansion cohort evaluate point mutation , structural change copy number event . ( EXPANSION PORTION ) XI . To evaluate damaging effect irinotecan combination irinotecan ABT-888 examining level Rad51 formation tumor . ( EXPANSION PORTION ) XII . To evaluate percentage breast cancer stem cell ( BCSC ) serial breast tumor biopsy irinotecan alone 1 cycle treatment combination irinotecan ABT-888 . ( EXPANSION PORTION ) XIII . To perform molecular profile tumor cell BCSC population irinotecan alone 1 cycle treatment combination irinotecan ABT-888 . ( EXPANSION PORTION ) XIV . To compare Rad51 foci aldehyde dehydrogenase-positive ( ALDH+ ) stem cell population bulk tumor cell . ( EXPANSION PORTION ) XV . To develop assay detect trap PARP1 2 tumor biopsy tissue response treatment irinotecan plus PARP inhibitor , case ABT-888 . ( DOSE ESCALATION FOR INTERMITTENT ABT-888 PORTION ) XVI . Additional exploratory assay name later . ( DOSE ESCALATION FOR INTERMITTENT ABT-888 PORTION ) XVII . To determine tumor response assess Response Evaluation Criteria Solid Tumors ( RECIST ) expansion cohort 12 triple-negative breast cancer ( BRCA ) -mutant breast cancer patient . OUTLINE : This dose-escalation study veliparib . Patients assign 1 3 cohort . DOSE ESCALATION : Patients receive irinotecan hydrochloride intravenously ( IV ) 90 minute day 1 8 veliparib orally ( PO ) twice daily ( BID ) day -1 14 ( day 3-14 course 1 ) . Courses repeat every 21 day absence disease progression unacceptable toxicity . EXPANSION PORTION : Patients receive irinotecan hydrochloride IV 90 minute day 1 8 veliparib PO BID day 1-15 ( day 2-15 course 1 ) . Courses repeat every 21 day absence disease progression unacceptable toxicity . INTERMITTENT DOSE ESCALATION : Patients receive irinotecan hydrochloride IV 90 minute day 3 10 veliparib PO BID day 1 4 8-11 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Patients must histologically cytologically confirm diagnosis malignancy metastatic unresectable standard curative palliative measure exist longer effective CPT11 treatment would viable therapy regimen ; patient solid hematologic malignancy ( Hodgkin 's nonHodgkin 's lymphoma ) may include long bone marrow perform within 6 week treatment Patients enrolled expansion portion study consist two cohort : patient triplenegative , BRCAmutant positive patient triplenegative , nonBRCA mutate breast cancer Patients enrol dose escalation intermittent ABT888 portion study must histologically cytologically confirm diagnosis malignancy metastatic unresectable standard curative palliative measure exist longer effective CPT11 treatment would viable therapy regimen ; patient solid hematologic malignancy ( Hodgkin 's nonHodgkin 's lymphoma ) may include long bone marrow perform within 6 week treatment ; recommend phase 2 dose determine , additional patient enrol MUST deleterious mutation BRCA human epidermal growth factor receptor 2 ( Her2 ) negative , estrogen receptor ( ER ) negative ( define less 1 % ER immunohistochemistry [ IHC ] ) progesterone receptor ( PR ) negative breast cancer ( define less 1 % PR stain IHC ) Patient must measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) guideline Patients must tumor determine easily accessible biopsy ( e.g . pleuralbased lesion , peripheral lymph node , soft tissue metastasis , large liver metastasis , etc ) Prior chemotherapy allow ; patient must receive chemotherapy 4 week prior initiation study treatment must full recovery acute effect prior chemotherapy ; patient must nitrosoureas mitomycin C 6 week prior initiation study treatment Prior radiation therapy allow ; patient must receive minimal radiation therapy ( = &lt; 5 % total marrow volume ) within 3 week prior initiation study treatment ; otherwise , patient must receive radiation therapy ( &gt; 5 % total marrow volume ) within 4 week prior initiation study treatment ; patient receive prior radiation 50 % total marrow volume exclude Prior experimental ( nonFood Drug Administration [ FDA ] approve ) therapy immunotherapies allow ; patient must receive therapy 4 week prior initiation study treatment must full recovery acute effect therapy Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Life expectancy great 12 week Absolute neutrophil count ( ANC ) &gt; = 1,500/mcL Platelets ( PLT ) &gt; = 100,000/mcL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x upper limit normal ( ULN ) ; liver metastases present , = &lt; 5 x ULN Bilirubin = &lt; 1.5 x ULN Creatinine = &lt; 1.5 x ULN OR calculate measure creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine institutional normal Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , three month follow completion study therapy ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document All patient must provide archival tissue block paraffin sample archival tissue block ( approximately 10 section ) use pharmacodynamic correlative study ( NOT require patient enrol dose escalation intermittent ABT888 portion study ) Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier ; patient administer ABT888 part single limit dose study , phase 0 study , necessarily exclude participate study solely receive prior ABT888 Patients may receive investigational agent within 4 week study entry History allergic reaction attribute follow : Camptothecin derivative ( e.g. , topotecan [ topotecan hydrochloride ] , irinotecan , exatecan [ exatecan mesylate ] ) Any ingredient contain within liquid irinotecan solution ( e.g. , sorbitol ) Any antiemetics antidiarrheal appropriate administration study therapy ( e.g. , loperamide dexamethasone ) Patients must receive anticancer therapy ( cytotoxic , biologic , radiation , hormonal replacement ) study except medication prescribe supportive care may potentially anticancer effect ( i.e . megestrol acetate , bisphosphonates ) ; medication must start 1 month prior enrollment study ; addition , men receive treatment prostate cancer maintain castrate level testosterone continuation luteinizingreleasing hormone agonists Patients active seizure history seizure Patients know active brain metastasis exclude clinical trial ; patient prior treat brain metastasis allow , provide accompany seizure baseline brain magnetic resonance imaging ( MRI ) scan prior study entry demonstrate current evidence brain metastasis ; patient central nervous system ( CNS ) metastases must stable &gt; 3 month treatment steroid treatment prior study enrollment Any patient require chronic maintenance white blood cell count granulocyte count use growth factor support ( e.g . Neulasta , Neupogen ) Any patient require cytochrome P450 family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) isoforminducing drug ( e.g . phenytoin , phenobarbital , carbamazepine , rifampin , rifabutin , ketoconazole , St. John 's wort ) exclude ; CYP3A4inducing drug discontinue least 2 week prior first cycle irinotecan Uncontrolled intercurrent illness include , limited : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated ABT888 Patients unable reliably tolerate and/or receive oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>